The global lupus therapeutics market size was valued at USD 2,500 million in 2021 and is projected to reach around USD 5,400 million in 2030 exhibiting a CAGR of 8.5% in the forecasted period. The rising prevalence of lupus, growing products approval and launches by market players are anticipated to upsurge the market growth. However, side effects related with drugs used for treatment of lupus are the factors are anticipated to hinder the growth of the market in the forecasted period.
The increasing prevalence of lupus disorders across the globe is one of the most important driving factors, impelling the growth in the global lupus therapeutics market. Moreover, the growing amount of investments, intended at developing high end and technically enabled healthcare arrangement and facilities in numerous developed as well as developing nations is also projected to foster the growth and development within the global lupus therapeutics market in upcoming years. The growing number of research and drug development and drug discovery projects under taken by the market players are also affecting the growth in the global lupus therapeutics market. However, the risk of adverse side effects caused by the medications and therapeutics in the global lupus therapeutics market may limit the industry’s growth in near future.
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was first reported from Wuhan, China in December 2019, and was stated as a global pandemic by the World Health Organization (WHO), which designates this SARS-CoV-2 infection as novel Coronavirus (COVID-19). As per the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread across the world infecting over 409 million population reaching to more than 5.8 million deaths as of February 13, 2022. The negative impact of COVID-19 on the healthcare sector is massive and it has considerably disturbed the healthcare industries’ complete supply chain, from raw materials to manufacturing and delivery. Likewise, the COVID-19 pandemic is expected to show a positive impact on the overall growth of the lupus therapeutics market owing to the association of COVID-19 with lupus. For instance, as per an article published by the Journal of Medical Case Reports in January 2021, connotation between COVID-19 and lupus is not yet determined but it recommends that COVID-19 could be a possible agent which is accountable for producing autoantibodies and causing systemic lupus erythematosus. There has been the first case of SLE manifestation following COVID-19 of a 39-year-old male in Iran reported by the same source.
Disease Type Insights
The systemic lupus erythematosus (SLE) segment led the market for lupus therapeutics and accounted for the largest revenue share of around 30% in 2021. Systemic lupus erythematosus is the most prevalent type of lupus that causes harm to several organs across the body such as the lungs, kidney, heart, and others. Systemic lupus erythematosus causes inflammation in the skin, lungs, joints, blood cells, kidneys, etc. This condition usually goes over cycles of flare-ups (symptoms appear) and remissions (symptoms disappear).
Route of Administration Insights
On the basis of route of administration, the market is segmented into oral, subcutaneous, intravenous and others. In 2021, the oral segment ruled the market for lupus therapeutics and held the largest market share of 38%. The oral segment is made up of small molecule drugs, which are considered the mainstream treatment for Lupus, and they are also simply managed. However, the second-largest share of the market was held by the intravenous segment in the forecasted year.
Region Insights
North America market dominated the global lupus therapeutics market in terms of demand and industry share. This trend can be accredited due to the existence of high number of important industry players as well as the presence of highly sophisticated and well-trenched medical and healthcare substructure in the region. Moreover, the increasing incidence of lupus disorders and developments in the diagnosis boost the growth of the lupus therapeutics market in this region. Furthermore, estimated approvals of new drugs and strong diagnosis plans for lupus will also contribute to the growth of the market in the Americas.
However, Asia-Pacific is anticipated to grow during the forecasted period owing to number of population and growing healthcare expenditure in this region.
Key Companies Insights
The market for lupus therapeutics is moderately competitive. With the rising applications of lupus therapeutics, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the lupus therapeutics market, ultimately boosting the market growth.
Some of the key companies working in the global lupus therapeutics market include:
• Hikma Pharmaceuticals PLC
• Lupus Therapeutics
• Dr. Reddy’s Laboratories Ltd.
• GlaxoSmithKline plc
• Amgen Inc.
• Novartis AG
• Sanofi
• UCB S.A.
• ImmuPharma PLC
• Bayer AG
• Merck & Co., Inc.
• Aurinia Pharmaceuticals Inc.
• Pfizer Inc.
• ADMA Biologics, Inc.
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International Gmbh
• Other players
Some of the Recent Developments:
• In December 2020, GlaxoSmithKline plc received the U.S. Food and Drug Administration (FDA) approval for its drug BENLYSTA (belimumab) to be used along with standard therapy for treatment of adult patients with active lupus nephritis (LN), a kidney disease caused due to SLE.
• In December 2017, Immupharma plc. developed a drug Lupozor that completed the phase 3 clinical study after receiving fast-track designation from the US Food and Drug Administration.
Segments
By Disease Type
• Systemic Lupus Erythematosus (SLE)
• Cutaneous Lupus Erythematosus
• Drug-Induced Lupus Erythematosus
• Neonatal Lupus
By Treatment Type
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Biologics
• Antimalarial Drugs
• Corticosteroids
• Others
By Route of Administration
• Oral
• Subcutaneous
• Intravenous
• Others
By End User
• Hospitals & Clinics
• Diagnostic Laboratories
• Others
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt
The main goals of report are:
- To examine and assignment the extent of the international market for the market sector.
- To Researching the important gamers globally, their SWOT analysis, market value, and market share.
- To identify, describe, and mission market based totally on type, quit use, and geography.
- To take a look at the market advantages, challenges, dangers, and constraints in the world’s principal regions.
- To pick out key traits and variables that are advertising or inhibiting market growth.
- To decide the excessive increase segments in order to have a look at the market potentialities for stakeholders.
- To consider every submarket fastidiously in phrases of its very own boom sample and market contribution.
- To know market possessions, agreements, growth, and the introduction of new merchandise as aggressive advances.
- To strategically discover the essential gamers and completely take a look at their enlargement plans.
